Market News & Trends
Kamada Announces Plan for Phase II/III Clinical Trial
Kamada Ltd. recently announced the clinical plan for the initiation of a Phase II/III clinical trial in the United States of its Alpha-1 Antitrypsin (G1-AAT…
Atara Bio to Present Results From Phase II Trial
Atara Biotherapeutics, Inc. recently announced Phase II results from its allogeneic T-cell product candidate, CMV-CTL, will be presented by its collaborating investigators at Memorial Sloan…
MorphoSys & LEO Pharma Enter Strategic Alliance
MorphoSys AG and LEO Pharma recently announced they have entered into a strategic alliance for the discovery and development of therapeutic antibodies for the treatment…
BioSun & ARTES Announce Co-Development Agreement for HPV Vaccine
BioSun Pharmed and ARTES Biotechnology recently announced they will join forces for the development and manufacturing of a HPV (human papilloma virus) vaccine in Iran.…
Aclaris Therapeutics Submits IND Application for ATI-50001
Aclaris Therapeutics, Inc. recently announced that it has submitted an Investigational New Drug Application (IND) to the US FDA for its drug candidate ATI-50001 for…
Parion Sciences Announces Presentation of Clinical Data With Novel Pulmonary Delivery Device
Parion Sciences, a company dedicated to the development of novel treatments for pulmonary and ocular diseases, recently announced that an abstract from its pulmonary research…
Daiichi Sankyo & Inspirion Delivery Sciences Announce Licensing Agreement
Daiichi Sankyo, Inc. and Inspirion Delivery Sciences LLC recently announced the companies have entered into a strategic collaboration agreement in the US to commercialize FDA-approved…
BIOPHYTIS Chooses Patheon to Produce Clinical Batches
BIOPHYTIS recently announced it has entered into an agreement with US firm Patheon for the industrial scale-up and manufacturing of clinical batches, the first stage…
Selecta Biosciences Initiates Phase II Clinical Trial
Selecta Biosciences, Inc. recently announced it has dosed the first patient in its Phase II clinical trial of SEL-212, the company’s lead proprietary immunotherapeutic product…
Proteon Therapeutics Announces Overview of Phase I Clinical Program
Proteon Therapeutics, Inc. recently announced that an overview of the company’s Phase I clinical program of investigational vonapanitase in peripheral artery disease (PAD) was presented…
Pluristem Signs Term Sheet for $30-Million Equity Investment Agreement
Pluristem Therapeutics Inc. recently announced it has signed a term sheet for an investment of approximately $30 million by China-based Innovative Medical Management Co., Ltd.,…
Viral Gene Announces Breakthrough in Colon Cancer
Philadelphia, PA – October 28, 2016 - Colorectal cancer kills more than 49,000 Americans each year and is the second-leading cause of cancer deaths in…
Molex Completes Acquisition of Phillips-Medisize Corporation
Molex, a global manufacturer of complete interconnect solutions, has completed its previously announced acquisition of Phillips-Medisize Corporation, a portfolio company of the San Francisco, CA-based…
Theravance Biopharma & Mylan Announce Positive Results From Two Pivotal Phase III Studies
Theravance Biopharma, Inc. and Mylan N.V. recently announced positive results from two replicate Phase III efficacy studies of revefenacin (TD-4208), an investigational long-acting muscarinic antagonist…
Merus Receives Milestone Payment from Ono Pharmaceutical
Merus N.V., a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, recently announced that the company received an undisclosed milestone payment from Ono Pharmaceutical Co.,…
Catalent Celebrates Ground Breaking for Expanded Biologics
Catalent Pharma Solutions, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, celebrated its ground breaking…
Oral OTEZLA Receives Positive NICE Recommendation for Adults With Chronic Plaque Psoriasis
Celgene recently announced that adult patients in England and Wales with chronic plaque psoriasis will now have access to oral OTEZLA (apremilast) following a positive…
Boston Biomedical Initiates Global Phase III Study
Boston Biomedical recently announced dosing of the first patient in CanStem303C, a new global Phase III study investigating napabucasin in combination with standard of care…
Abeona Therapeutics Provides Update From Phase I/II Clinical Trial
Abeona Therapeutics Inc. recently provided at the Orphan Drugs & Rare Disease Conference (London, UK), an update on clinical results through 30 days post-injection for…
Sedia Biosciences & Floragenex Announce Completion of Merger
Sedia Biosciences Corporation and Floragenex Inc. recently announced the merger of their companies. Details of the transaction were not disclosed. Sedia will continue the business…
